Basic and clinical studies of gatifloxacin in oral surgery

• Published in: Japanese Journal of Chemotherapy Vol. 47; no. Supplement2; pp. 402 - 418
• Main Authors: Kaneko, Akihiro, Shiiki, Kazuo, Yamamoto, Tadashi, Michiwaki, Yukihiro, Ohno, Tomoya, Kanno, Kazuyuki, Yamane, Nobuo, Sasaki, Jiro, Michi, Kenichi
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society of Chemotherapy 1999; 公益社団法人 日本化学療法学会
• Subjects: AM-1155; GFLX; フルオロキノロン系抗菌薬; 歯科・口腔外科領域感染症; 組織移行
• ISSN: 1340-7007; 1884-5886
• DOI: 10.11250/chemotherapy1995.47.Supplement2_402

We performed experimental and clinical studies on gatifloxacin, a new synthetic antimicrobial agent, for oral use in the field of oral surgery. 1. A single dose of 150 mg of gatifloxacin (GFLX) was administered to 16 patients.Concentrations of GFLX in gingiva were 0.97-7.28 μg/g 1.1-12 hours after administration in 14 subjects; those in alveolar bone were 0.13 μg/g at 3.5-12 hours in 2 subjects; and those in cyst, 3.51μg/g at 2.6 hours in 1 subject; and in palatine mucosa, 1.67 μg/g at 12 hours in 1 subject. 2. A single dose of 100 mg of GFLX was administered to 45 patients, and concentrations found in tooth extraction wounds 0.2-5.6 hours later were < 0.01-1.59 μg/g. 3. A clinical study was conducted in 104 patients with odontogenic infections. The efficacy rate judged by comparative score evaluation was 85.1% for 67 patients, while that by doctors was 82.9 % for 76 patients. 4.Side effects were observed in eight cases (diarrhea, rash, sleepiness, nausea, discomfort, dizziness, headache, dullness). Abnormal laboratory findings were recognized in two cases (mild increase in eosinophils and slight elevation of S-GPT, Al-p). Based on these results, we conclude that gatifloxacin is a useful antimicrobial agent for the treatment of odontogenic infections at a dose of 200-400 mg/day.